The expressions of TXNDC11 mRNA and protein in tumor tissue and corresponding paracancerous tissue were analyzed using ONCOMINE database and TIMER database. The expression difference of TXNDC11 protein between tumor tissue and normal tissue was analyzed by Clinical Proteomic Tumor Analysis Consortium （CPTAC） database. The correlations between the TXNDC11 protein expression and pan-cancer stages were analyzed using Gene Expression Profile Interactive Analysis （GEPIA） database. The relationship between TXNDC11 expression and survival prognosis of patients with pan-cancer was analyzed using online Kaplan Meier plotter. The correlations between the TXNDC11 protein expression and tumor- infiltrating immune cells were studied by TIMER database. The relationship between TXNDC11 protein and immune checkpoint was analyzed using Sangerbox database.

The ONCOMINE database analysis results showed that compared with paracancerous normal tissue， the expression levels of TXNDC11 mRNA in colon adenocarcinoma（COAD），stomach adenocarcinoma（STAD） and sarcoma（SARC） tissues were decreased significantly （P<0.01）， while the expression levels of TXNDC11 mRNA in breast cancer（BRCA），esophageal carcinoma（ESCA）， kidney chromophobe（KICH） and pancreatic adenocarcinoma（PAAD） tissues were increased （P<0.01）. In TIMER database，the expression levels of TXNDC11 protein in BRCA， cholangiocarcinoma（CHOL）， glioblastoma multiforme（GBM）， head and neck squamous cell carcinoma（HNSC） and prostate adenocarcinoma（PRAD） tissues were increased，and the TXNDC11 protein expression levels in COAD，kidney renal papillary cell carcinoma（KIRP），lung adenocarcinoma（LUAD）， lung squamous cell carcinoma（LUSC），pheochromocytoma and paraganglioma（PCPG），rectum adenocarcinoma（READ） and thyroid carcinoma（THCA） tissues were signifcantly decreased.The CPTAC database analysis showed that the protein expression levels of TXNDC11 in kidney renal clear cell carcinoma（KIRC） and uterine corpus endometrial carcinoma（UCEC） were significantly higher than those in normal tissue （P<0.01），but theexpression levels of TXNDC11 protein in BRCA，ovarian cancer（OV） and COAD tissues were lower than those in normal tissue （P<0.05）.The expression level of TXNDC11 protein in GEPIA database was closely related to the clinical characteristics and pathological stages of LUAD，ovarian serous cystadenocarcinoma， THCA and UCEC patients（P<0.05）.In Kaplan Meier plotter database， the high expressions of TXNDC11 in bladder urothelial carcinoma （BLCA） （HR=0.71，P=0.024）， BRCA（HR=0.68， P=0.021）， ESCA （HR=0.39，P=0.005 1），HNSC （HR=0.72，P=0.026）， KIRC（HR=0.41，P=0.002 6），LUAD（HR=0.53，P<0.01），READ（HR=0.34，P=0.014），SARC（HR=0.61，P=0.016），thymoma （THYM）（HR=0.14， P=0.004 2），THCA（HR=0.35，P=0.043） and UCEC（HR = 0.36， P<0.01） tissues were associated with the better prognosis of the patients. The TIMER database analysis results showed that TXNDC11 was significantly correlated with the levels of B cell infiltration in 22 kinds of tumor tissues（P<0.05）；in addition， the expression of TXNDC11 was significantly correlated with the infiltration levels of CD4 + T cells in 16 kinds of tumor tissues，CD8 +^{T cells in 25 kinds of tumor tissues， neutrophils in 22 kinds of tumor tissues，macrophages in 22 kinds of tumor tissues and the dendritic cells in 23 kinds of tumor tissues （P<0.05）；TXNDC11 protein expression was significantly correlated with immune cells in COAD， LUSC， HNSC， SARC and skin melanoma （SKCM）（P<0.01）.The Sangerbox database analysis results showed that TXNDC11 protein was significantly correlated with the expression levels of multiple immune checkpoint genes in a variety of tumor tissues （P<0.05）.}

In pan-cancer analysis， TXNDC11 is generally low expressed in a variety of tumor tissue， and TXNDC11 is significantly correlated with the prognosis and survival of patients with a few of tumors. Therefore， TXNDC11 can be used as an important predictor of tumor prognosis and regulate the various tumor-related immune responses in a certain degree.